TACE联合射频消融治疗结肠癌肝转移患者的临床疗效

doi:10.3877/cma.j.issn.2095-3232.2015.01.009

中华肝脏外科手术学电子杂志 ›› 2015, Vol. 04 ›› Issue (01) : 31 -34. doi: 10.3877/cma.j.issn.2095-3232.2015.01.009

所属专题：文献；

临床研究

TACE联合射频消融治疗结肠癌肝转移患者的临床疗效

何科¹, 王晶¹, 徐丽南², 瞿虎²^,^†(

), 江春强², 柯嘉², 俞建东², 苏中振³, 尧冰⁴

^1. 510080　广州，中山大学附属第一医院妇产科
^2. 510655　广州，中山大学附属第六医院外一科
^3. 510630　广州，中山大学附属第三医院超声科

收稿日期:2014-11-12 出版日期:2015-02-10
通信作者: 瞿虎
基金资助:
广东省科技计划项目(2011B031300016)

Clinical efficacy of TACE combined with radiofrequency ablation in the treatment of liver metastasis of colon cancer

Ke He¹, Jing Wang¹, Linan Xu², Hu Qu²^,^†(), Chunqiang Jiang², Jia Ke², Jiandong Yu², Zhongzhen Su³, Bing Yao⁴

^1. Department of Obstetrics and Gynecology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
^2. First Department of Surgery, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China
^4. Department of Ultrasonography, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

Received:2014-11-12 Published:2015-02-10
Corresponding author: Hu Qu
About author:
Corresponding author: Qu Hu, Email: quhu74@hotmail.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

何科, 王晶, 徐丽南, 瞿虎, 江春强, 柯嘉, 俞建东, 苏中振, 尧冰. TACE联合射频消融治疗结肠癌肝转移患者的临床疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2015, 04(01): 31-34.

Ke He, Jing Wang, Linan Xu, Hu Qu, Chunqiang Jiang, Jia Ke, Jiandong Yu, Zhongzhen Su, Bing Yao. Clinical efficacy of TACE combined with radiofrequency ablation in the treatment of liver metastasis of colon cancer[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(01): 31-34.

目的

探讨TACE联合射频消融（RFA）治疗结肠癌肝转移的临床疗效。

方法

本前瞻性研究对象为2007年6月至2011年5月中山大学附属第六医院收治的68例结肠癌肝转移患者。所有患者均签署知情同意书，符合医学伦理学规定。其中男43例，女25例；平均年龄（59±4）岁。按随机数字表法将患者分为RFA组和对照（Control）组，每组34例。两组患者均先进行TACE，RFA组在TACE治疗3周后行RFA。两组均于治疗前后采用流式细胞术检测CD3⁺、CD4⁺、CD8⁺阳性细胞百分率和CD4⁺/CD8⁺比值。观察两组患者治疗后肿瘤直径及总体疗效。患者接受随访，观察肿瘤复发和患者存活情况。两组患者肿瘤直径及免疫功能检测数据比较采用t检验，两组疗效比较采用秩和检验，生存分析采用Log-rank法和Z检验。

结果

治疗后RFA组CD4⁺、CD8⁺及CD4⁺/CD8⁺比值分别为（42±4）%、（13±3）%、2.9±0.9，与Control组的（33±4）%、（17±3）%、2.3±0.9比较差异有统计学意义（t=5.483，-6.488，9.321；P<0.05）。治疗后RFA组肿瘤直径为（0.9±0.1） cm，明显小于Control组的（1.9±0.2） cm （t=-4.573，P<0.05）。RFA组术后总有效率为62%（21/34），Control组为35%（12/34），RFA组治疗效果优于Control组（Z=4.769，P<0.05）。RFA组2、3年生存率分别为38.2%、23.5%，明显高于Control组的14.7%、5.9%（Z=4.836，4.221；P<0.05）。

结论

TACE联合RFA治疗结肠癌肝转移是一种安全、有效的治疗方案,其疗效可能与改善机体免疫功能有关。

关键词: 结肠肿瘤, 肝肿瘤, 肿瘤转移, 消融技术, 化学栓塞，治疗性

Objective

To investigate the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in treatment of liver metastasis of colon cancer.

Methods

A total of 68 patients with liver metastasis of colon cancer in the Sixth Affiliated Hospital of Sun Yat-sen University from June 2007 to May 2011 were enrolled in this prospective study. The informed consents of all patients were obtained and local ethical committee approval had been received. There were 43 males and 25 females with a mean age of (59±4) years old. The patients were divided into RFA group and Control group with 34 cases in each group according to random number table method. Patients in both groups underwent TACE firstly and patients in RFA group underwent RFA 3 weeks after TACE treatment. Cluster of differentiation (CD) 3⁺, CD4⁺, CD8⁺ positive cell percentage and CD4⁺/CD8⁺ ratio were defined by flow cytometry before and after treatments in two groups. The tumor diameter after treatments and general efficacy were observed. The patients were followed up and the tumor recurrence and survival of the patients were observed. The comparisons of tumor diameter and immune function between two groups were conducted using t test. The comparison of efficacy between two groups was conducted using rank sum test. The survival analysis was conducted using Log-rank test and Z test.

Results

The CD4⁺, CD8⁺ percentage and CD4⁺/CD8⁺ ratio were (42±4)%, (13±3)%, 2.9±0.9 in RFA group after treatment and were (33±4)%, (17±3)%, 2.3±0.9 in Control group, where significant differences were observed (t=5.483, -6.488, 9.321; P<0.05). The tumor diameter in RFA group after treatment [(0.9±0.1) cm] was significantly smaller than that in Control group [(1.9±0.2) cm] (t=-4.573, P<0.05). The total effective rate in RFA group was 62%(21/34) and was 35%(12/34) in Control group. The treatment efficacy of RFA group was better than that of Control group (Z=4.769, P<0.05). The 2-, 3-year survival rates in RFA group (38.2%, 23.5%) were significantly higher than those in Control group (14.7%, 5.9%) (Z=4.836, 4.221; P<0.05).

Conclusions

TACE combined with RFA is a safe and effective regimen in treating liver metastasis of colon cancer. The efficacy may be associated with the improvement of the body’s immune function.

Key words: Colonic neoplasms, Liver neoplasms, Neoplasm metastasis, Ablation techniques, Chemoembolization, therapeutic

表1 两组结肠癌肝转移患者一般资料比较

组别	例数	性别（例）		年龄（岁，±s）	肿瘤直径（cm，±s）
组别	例数	男	女	年龄（岁，±s）	肿瘤直径（cm，±s）
RFA组	34	21	13	60±4	2.8±0.6
Control组	34	22	12	59±4	2.9±0.5
统计值	?	χ²=0.237		t=0.731	t=-0.231
P值	?	>0.05		>0.05	>0.05

表1 两组结肠癌肝转移患者一般资料比较

组别	例数	性别（例）		年龄（岁，±s）	肿瘤直径（cm，±s）
组别	例数	男	女	年龄（岁，±s）	肿瘤直径（cm，±s）
RFA组	34	21	13	60±4	2.8±0.6
Control组	34	22	12	59±4	2.9±0.5
统计值	?	χ²=0.237		t=0.731	t=-0.231
P值	?	>0.05		>0.05	>0.05

表2 两组结肠癌肝转移患者治疗前后免疫功能比较（±s）

组别	例数	CD3⁺（%）		CD4⁺（%）		CD8⁺（%）		CD4⁺/CD8⁺
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
RFA组	34	43±4	70±4	26±3	42±4	20±4	13±3	1.8±0.7	2.9±0.9
Control组	34	41±3	52±4	27±4	33±4	20±3	17±3	1.8±0.8	2.3±0.9
t值	?	0.731	7.548	-0.361	5.483	-0.773	-6.488	-0.361	9.321
P值	?	>0.05	<0.05	>0.05	<0.05	>0.05	<0.05	>0.05	<0.05

表2 两组结肠癌肝转移患者治疗前后免疫功能比较（±s）

组别	例数	CD3⁺（%）		CD4⁺（%）		CD8⁺（%）		CD4⁺/CD8⁺
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
RFA组	34	43±4	70±4	26±3	42±4	20±4	13±3	1.8±0.7	2.9±0.9
Control组	34	41±3	52±4	27±4	33±4	20±3	17±3	1.8±0.8	2.3±0.9
t值	?	0.731	7.548	-0.361	5.483	-0.773	-6.488	-0.361	9.321
P值	?	>0.05	<0.05	>0.05	<0.05	>0.05	<0.05	>0.05	<0.05

表3 两组结肠癌肝转移患者治疗效果比较

组别	例数	完全缓解（例）	部分缓解（例）	稳定（例）	进展（例）	总有效率（%）
RFA组	34	6	15	7	6	63
Control组	34	2	10	10	12	35
Z值	?	?	?	4.769	?	?
P值	?	?	?	<0.05	?	?

表3 两组结肠癌肝转移患者治疗效果比较

组别	例数	完全缓解（例）	部分缓解（例）	稳定（例）	进展（例）	总有效率（%）
RFA组	34	6	15	7	6	63
Control组	34	2	10	10	12	35
Z值	?	?	?	4.769	?	?
P值	?	?	?	<0.05	?	?

表4 两组结肠癌肝转移患者治疗后生存率比较（%）

组别	例数	1年	2年	3年
RFA组	34	67.6	38.2	23.5
Control组	34	50.0	14.7	5.9
Z值	?	2.186	4.836	4.221
P值	?	>0.05	<0.05	<0.05

表4 两组结肠癌肝转移患者治疗后生存率比较（%）

组别	例数	1年	2年	3年
RFA组	34	67.6	38.2	23.5
Control组	34	50.0	14.7	5.9
Z值	?	2.186	4.836	4.221
P值	?	>0.05	<0.05	<0.05

[1]	Leone F, Artale S, Marino D, et al. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: the MetaPan study[J]. Cancer, 2013, 119(19):3429-3435.
[2]	Vandenhende MA, Buret J, Camou F, et al. Successful daptomycin lock therapy for implantable intra-arterial catheter infection in a patient with liver metastases of colon cancer[J]. Diagn Microbiol Infect Dis, 2014, 78(4):497-498.
[3]	Yoshida Y, Hoshino S, Miyake T, et al. Early start of chemotherapy after resection of brain metastasis from colon cancer with synchronous multiple liver metastases[J]. Case Rep Oncol, 2012, 5(2):290-295.
[4]	Abbott AM, Parsons HM, Tuttle TM, et al. Short-term outcomes after combined colon and liver resection for synchronous colon cancer liver metastases: a population study[J]. Ann Surg Oncol, 2013, 20(1):139-147.
[5]	Yang KH, Ryu JH, Moon KM, et al. More than 7-year survival of a patient following repeat hepatectomy for total 20 colon cancer liver metastases[J]. J Korean Surg Soc, 2012, 82(2):128-133.
[6]	Vogl TJ, Gruber-Rouh T, Eichler K, et al. Response to comment on "repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results": will there be clinical implications in the future?[J]. Eur J Radiol, 2013, 82(9):1592-1594.
[7]	Farouil G, Deschamps F, Hakime A, et al. Coil-assisted RFA of poorly visible liver tumors: effectiveness and risk factors of local tumor progression[J]. Cardiovasc Intervent Radiol, 2014, 37(3):716-722.
[8]	Nielsen K, van Tilborg AA, Meijerink MR, et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases[J]. World J Surg, 2013, 37(6):1340-1347.
[9]	李凯，刘波，曾庆劲，等．虚拟导航计划系统辅助肝细胞肝癌射频消融[J/CD]．中华肝脏外科手术学电子杂志，2012，1(2):94-99.
[10]	Nobuoka D, Motomura Y, Shirakawa H, et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes[J]. Int J Oncol, 2012, 40(1):63-70.
[11]	Furusaka T, Matuda H, Saito T, et al. Long-term observations and salvage operations on patients with T₂N₀M₀ squamous cell carcinoma of the glottic larynx treated with radiation therapy alone[J]. Acta Otolaryngol, 2012, 132(5):546-551.
[12]	Zhou B, Wang J, Yan Z, et al. Liver cancer: effects, safety, and cost-effectiveness of controlled-release oxycodone for pain control after TACE[J]. Radiology, 2012, 262(3):1014-1021.
[13]	Stintzing S, Grothe A, Hendrich S, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases[J]. Acta Oncol, 2013, 52(5):971-977.
[14]	Carrafiello G, Fontana F, Cotta E, et al. Ultrasound-guided thermal radiofrequency ablation (RFA) as an adjunct to systemic chemotherapy for breast cancer liver metastases[J]. Radiol Med, 2011, 116(7):1059-1066.
[15]	Guan HT, Wang J, Yang M, et al. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients[J]. Chin Med J, 2013, 126(19):3651-3655.
[16]	Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J]. Hepatology, 2013, 57(4):1448-1457.
[17]	Chen MS, Peng ZW, Xu L, et al. Role of radiofrequency ablation in the treatment of hepatocellular carcinoma: experience of a cancer center in China[J]. Oncology, 2011, 81 Suppl 1:100-104.

[1]	章建全, 程杰, 陈红琼, 闫磊. 采用ACR-TIRADS评估甲状腺消融区的调查研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(10): 966-971.
[2]	高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[3]	常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4]	赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[5]	李云龙, 夏旭良, 江志强, 刘伟, 刘凯, 唐立, 刘昊中, 张思远. 三种方法治疗分化型甲状腺癌的临床疗效[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 487-489.
[6]	崔宏帅, 冯丽明, 东维玲, 韩博. 腹腔镜右半结肠癌D3根治术+IGLN清扫术治疗局部进展期结肠肝曲癌的临床效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 566-569.
[7]	丁志翔, 于鹏, 段绍斌. 血浆BRAF基因检测对腹腔镜右半结肠癌D3根治术中行幽门淋巴结清扫的指导价值[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 570-573.
[8]	公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[9]	李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[10]	陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[11]	张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[12]	吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[13]	关国欣, 罗福文. 结肠癌合并急性梗阻的个性化处理[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 459-463.
[14]	石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[15]	靳英, 付小霞, 陈美茹, 袁璐, 郝力瑶. CD147调控MAPK信号通路对结肠癌细胞增殖和凋亡的影响及机制研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 474-480.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical efficacy of TACE combined with radiofrequency ablation in the treatment of liver metastasis of colon cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical efficacy of TACE combined with radiofrequency ablation in the treatment of liver metastasis of colon cancer